期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌患者胸水来源树突状细胞增强CIK细胞的杀伤作用 被引量：5

Enhancement of cytotoxic effect of cytokine induced killer cells by dendritic cells derived from malignant pleural effusion in patients with lung cancer
下载PDF
导出
摘要 肺癌是所有恶性肿瘤病死率中增长最快、危害最大的恶性肿瘤之一。由于就诊时多为晚期，即使经手术、化疗及放疗后，患者的生存质量仍难以改变，且预后极差。利用免疫效应细胞治疗作为辅助疗法，消除患者体内残留的肿瘤细胞，可改善患者的生存质量。细胞因子诱导的杀伤细胞（CIK）是一种新型的免疫效应细胞，具有增殖倍数高、细胞毒性强、抗瘤谱广、对化疗耐药细胞株敏感等特点，在肿瘤免疫治疗中有较大价值。DC是目前已知功能最强的抗原提呈细胞，
作者 张才擎 张嵩 王红梅
机构地区 山东省立医院呼吸科 山东省立医院妇产科
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2006年第2期142-144,共3页 Chinese Journal of Cancer Biotherapy
关键词 DC 细胞因子诱导的杀伤细胞 肺癌 胸水
分类号 R730.3 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Yanagawa H, Takeuchi E, Suzuki Y, et al. Presence and potent immunosuppressive role of interleukin-10 in malignant pleural effusion due to lung cancer[J]. Cancer Lett. 1999, 136 ( 1 ) : 27-32.
  • 2Yanagawa H, Takeuchi E, Suzuki Y. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer[J]. Cancer Immunol Immunother, 1999, 48(7) : 396-400.
  • 3Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma modle to evaluate cytokine-induced killer cells with potent antitumor cell activity [ J]. J Exp Med, 1991,174(1) : 139-149.
  • 4Scheffold C, Brandt K, Johnston V, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia[ J]. Bone Marrow Transplant, 1995,15(1) : 33-39.
  • 5Schmidt-Wolf IG, Lefterova P, Johnston V, et al, Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells [J]. Cell Immunol, 1996, 169(1):85-90.
  • 6张嵩,王恩忠,白春学,徐永华.共培养的树突状细胞与CIK细胞的体外增殖和杀瘤活性研究[J].实验生物学报,2003,36(5):375-380. 被引量：14

二级参考文献16

  • 1Mehta, B.A., I.G. Schmidt-Wolf, I.L. Weissman and R. S. Negrin, 1995, Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3 + CD56 + killer cells. Blood, 86 :3493 - 3499.
  • 2Girolomoni, G. and P. Ricciandi-Lastagnoli, 1997, Dendritic cells hold promise for immumunotherapy. Immunol. Today. ,18:102- 104.
  • 3Shimizu, K. , R.C. Fields., M. Giedlin and J. J. Mule,1999, Systemic administration of interleukin 2 enhances therapeuticefficacy of dendritic cell-based tumor vaccines.Proc. Natl. Acad. Sci. USA., 96:2268 - 2273.
  • 4Schmidt, R.E., C. Murray, J. F. Daley, S.F. Schlossman and J. Ritz, 1986, A subset of natural killer cells inperipheral blood displays a mature T cell phenotype. J.Exp. Med. , 164:351-356.
  • 5Lanier, L.L., A.M. Le, C.I. Civin, M.R. Loken andJ.H. Phillips, 1986,The relationship of CD16(Leu-11)and Leul9(NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol., 136: 4480 - 4486.
  • 6Ortaldo, J.R., R.T. Winkler-Pickett, H. Yagita andH.A. Young , 1991, Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement and pore-forming protein expression. Cell Immunol., 136: 486 - 495.
  • 7Lu, P. and R.S. Negrin, 1994, A novel population of expanded human CD3 + CD56 + cell derived from T ceilswith potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol., 153:1687- 1696.
  • 8Schmidt-Wolf, I.G., R.S. Negrin, H.P. Kiem, K.G.Blume and I.L. Weissman, 1991, Use of a SCID mouse/human lymphorna modle to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp.Med. 174:139 - 149.
  • 9Banchereau, J. and R. Steinman, 1998, Dendritic cells and the control of immunity. Nature, 392.245 - 252.
  • 10Hsu, F. J.G. and F. Benike, . 1996,Vaccination of patients with B-cell lymphoma using antologous antigenpulsed antigen-pulsed dendritic cells. Nature. Med. , 2.52 - 58.

共引文献13

同被引文献86

引证文献5

二级引证文献25

中国肿瘤生物治疗杂志
2006年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部